Sorafenib Tosylate | Anticancer Tyrosine Kinase Inhibitor, 99% Purity, USP/EP Certified
✧ Product Overview
Sorafenib Tosylate is a multitarget tyrosine kinase inhibitor approved for advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and thyroid cancer. It inhibits VEGFR, PDGFR, and RAF kinases, blocking tumor angiogenesis and proliferation. As the active ingredient in Nexavar®, it is widely used in first-line therapy for unresectable liver and kidney cancers.
✧ Key Advantages
🔹 High Potency & Selectivity
🔹 Broad-Spectrum Antitumor Activity
Dual action: suppresses tumor growth and angiogenesis45.
Effective against BRAF-mutated cancers (e.g., melanoma)4.
🔹 Oral Bioavailability
✧ Applications
Hepatocellular Carcinoma (HCC): First-line treatment for advanced stages13.
Renal Cell Carcinoma (RCC): Standard therapy for metastatic cases13.
Thyroid Cancer: Approved for radioactive iodine-resistant tumors35.
Clinical Research: Investigated for NSCLC and melanoma45.
✧ Quality Certifications
Complies with USP/EP/BP monographs23.
Batch-specific COA with HPLC, NMR, and residual solvent analysis67.
Stability tested under ICH Q1A guidelines (24-month shelf life)67.
✧ Market Trends
The global oncology kinase inhibitor market is projected to grow at CAGR 8.5% (2025–2030), driven by rising HCC/RCC prevalence35. Sorafenib Tosylate remains a cornerstone therapy, with $1.2 billion annual sales in 2024, supported by its proven efficacy and expanding off-label applications35.
China
